An ongoing dialogue on HIV/AIDS, infectious diseases,
July 14th, 2016
Must-Read Item: This Year’s JAMA HIV/AIDS Issue
The folks over at the Journal of the American Medical Association have been doing a periodic HIV/AIDS themed issue for years, generally around the time of the International AIDS Conference.
The latest issue is out this week, and it’s terrific. Here are some highlights:
- In serodiscordant couples practicing “condomless sex”, there were zero transmissions if the infected partner was on suppressive HIV therapy. If you’re keeping score, the estimated number of sexual contacts in this ambitious cohort study was 58,000 (36,000 heterosexual, 22,000 MSM). Statistically-inclined nerds will point out that you can’t really say the risk is zero — there’s a 95% confidence interval around this zero estimate, you can read the upper limit in the full paper, both for the heterosexual and MSM groups. Plus, with a median f/u of only 1-2 years, of course further study is required for a more precise estimate of risk. Despite these limitations and others — well-described in the excellent accompanying editorial — we all must admit that ZERO transmissions to date is a very good start! And we should heartily thank the study investigators for introducing a nifty new word to the medical/ID lexicon — “condomless” is vastly preferable “acondomic” or “condomopenic”, though that last one might make more people smile.
- For our most challenging patients, providing “patient navigation” and financial incentives did not improve virologic suppression rates compared with standard-of-care. The inclusion criteria for participation in this study were just the things that usually exclude patients from other trials — they were hospitalized, with addiction, psychiatric disease, had poor compliance with ART, terrible outpatient follow-up — you get the idea, challenging. They were randomized to 1) usual care; 2) “patient navigation” (intensive case management); 3) patient navigation plus financial incentives. During the 6 month intervention, virologic outcomes were better in the patient navigation/financial incentives group, but 6 months after the interventions stopped the benefit wore off. I guess “pay for performance” works, but only while someone is paying! A fascinating and remarkable study.
- IAS-USA HIV Guidelines Updated. With the upfront disclosure that I was part of the panel that wrote these guidelines, this sparkling new version covers it all — just in time for beach reading. Who should be treated (pretty much everyone), what to start (one of the integrase inhibitors plus TAF/FTC or, if it’s DTG, TAF/FTC or ABC/3TC), who should be switched and how to do it, how to treat in the context of OIs, how to retain people in care, what lab monitoring to do, and how to prevent transmission. Plus, this version took care of a couple of my minor pet peeves: MAC prophylaxis is not recommended to those with CD4 < 50 if they’re starting ART (hooray!), and, at the opposite extreme of the immunologic spectrum, CD4 cell count monitoring isn’t recommended if a patient is virologically suppressed and has CD4 consistently > 500 (hooray again!). I’ll now have to find something else to complain about (maybe the use of the term “HAART” — still trying to get rid of that one).
- A bunch of other interesting reads. An encouraging “demonstration project” on PrEP in community based clinics. Tony Fauci on the updated prospects of an HIV vaccine in the era of broadly neutralizing antibodies. (He could probably write a piece like this in his sleep — and I mean that in the most admiring way possible!) Gerry Friedland on the historic and symbolic importance of this year’s International AIDS Conference returning to Durban. An interview with transplant surgeon Dorry Segev on the challenges of organ transplantation among patients with HIV, in particular the use of HIV-infected donors for these individuals (which makes abundant sense on multiple levels, including the availability of organs for HIV-negative patients).
Hey, remember when JAMA had art on the cover? (And yes, I miss that.) The 1996 cover to the HIV/AIDS issue was famously blank (see image above), the absence of artwork making a strong statement about “the toll the virus has taken among artists and other creative persons who have died prematurely because of AIDS.”
Now, 20 years later, the current HIV/AIDS JAMA issue includes content that would have been unfathomable at that time. Little did we know that 1996 would be the pivotal year, the turning point when this rapidly fatal disease — then the leading cause of death among young Americans — would become both treatable and preventable.
Amazing progress.
Even “augmented reality” can’t compete.
[youtube https://www.youtube.com/watch?v=gEb4UFIuXLM&w=560&h=315]
(I predict 2-3 months for this Pokemon Go craze, but what do I know.)
Categories: Health Care, HIV, Patient Care, Policy
Tags: antiretroviral therapy, guidelines, HIV, IAS-USA
You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
One Response to “Must-Read Item: This Year’s JAMA HIV/AIDS Issue”

Paul E. Sax, MD
Associate Editor
NEJM Clinician
Biography | Disclosures & Summaries
Learn more about HIV and ID Observations.
Pages
Archives
- March 2026
- February 2026
- January 2026
- December 2025
- November 2025
- October 2025
- September 2025
- August 2025
- July 2025
- June 2025
- May 2025
- April 2025
- March 2025
- February 2025
- January 2025
- December 2024
- November 2024
- October 2024
- September 2024
- August 2024
- July 2024
- June 2024
- May 2024
- April 2024
- March 2024
- February 2024
- January 2024
- December 2023
- November 2023
- October 2023
- September 2023
- August 2023
- July 2023
- June 2023
- May 2023
- April 2023
- March 2023
- February 2023
- January 2023
- December 2022
- November 2022
- October 2022
- September 2022
- August 2022
- July 2022
- June 2022
- May 2022
- April 2022
- March 2022
- February 2022
- January 2022
- December 2021
- November 2021
- October 2021
- September 2021
- August 2021
- July 2021
- June 2021
- May 2021
- April 2021
- March 2021
- February 2021
- January 2021
- December 2020
- November 2020
- October 2020
- September 2020
- August 2020
- July 2020
- June 2020
- May 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
Categories
- Antiretroviral Rounds (21)
- Health Care (786)
- HIV (405)
- Infectious Diseases (619)
- Medical Education (129)
- Misc (55)
- Patient Care (522)
- Policy (230)
- Research (217)
- Uncategorized (1)
-
Tag Cloud
- Abacavir AIDS antibiotics antiretroviral therapy ART atazanavir baseball Brush with Greatness CDC C diff COVID-19 CROI darunavir dolutegravir elvitegravir etravirine FDA HCV hepatitis C HIV HIV cure HIV testing ID fellowship ID Learning Unit Infectious Diseases influenza Link-o-Rama lyme disease medical education MRSA PEP PrEP prevention primary care raltegravir Really Rapid Review resistance Retrovirus Conference rilpivirine sofosbuvir TDF/FTC tenofovir Thanksgiving vaccines zoster

While we’re at it, can we also get rid of “cART”? I go on a tirade every time I see it in a paper I’m asked to review. It’s even worse than “HAART.” AZT/3TC was “cART,” but it wasn’t “HAART.”